We evaluated their replication competence in cancer cells as well as their ability to elicit T cell responses against tumor neo-antigens, demonstrating the feasibility to obtain replication-efficient VACVs with an increased capacity to activate the IRF3 pathway. The gene discussed is IRF3; the disease is cancer.